Royalty Pharma (RPRX) Enterprise Value (2019 - 2026)
Royalty Pharma (RPRX) posted Enterprise Value of $2.4 billion for Q1 2026, down 6.17% sequentially from $2.6 billion in Q4 2025, and up 21.99% YoY from $2.0 billion in Q1 2025.
Royalty Pharma (RPRX) Enterprise Value (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Enterprise Value for 8 years, with the latest figure at $2.4 billion in Q1 2026.
- Quarterly Enterprise Value rose 21.99% year-over-year to $2.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 21.99% YoY) and the FY2025 annual result came in at $2.6 billion, up 7.97% from the prior year.
- Enterprise Value declined to $2.4 billion in Q1 2026 per RPRX's latest filing, from $2.6 billion in the prior quarter.
- Over five years, Enterprise Value peaked at $3.1 billion in Q4 2023 and troughed at $1.4 billion in Q2 2023.
- A 5-year average of $2.3 billion and a median of $2.4 billion in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value sank 44.83% in 2022, then surged 70.46% in 2025.
- Over 5 years, Enterprise Value stood at $2.2 billion in 2022, then jumped by 41.65% to $3.1 billion in 2023, then retreated by 21.35% to $2.4 billion in 2024, then grew by 7.97% to $2.6 billion in 2025, then dropped by 6.17% to $2.4 billion in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered $2.4 billion, $2.6 billion, and $2.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -3.15 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.12 Bn |
| Mar 31, 2026 | 2.44 Bn |
| Dec 31, 2025 | 2.60 Bn |
| Sep 30, 2025 | 2.25 Bn |
| Jun 30, 2025 | 2.51 Bn |
| Mar 31, 2025 | 2.00 Bn |
| Dec 31, 2024 | 2.41 Bn |
| Sep 30, 2024 | 2.39 Bn |
| Jun 30, 2024 | 1.47 Bn |
| Mar 31, 2024 | 2.49 Bn |
| Dec 31, 2023 | 3.06 Bn |
| Sep 30, 2023 | 2.50 Bn |
| Jun 30, 2023 | 1.36 Bn |
| Mar 31, 2023 | 1.89 Bn |
| Dec 31, 2022 | 2.16 Bn |
| Sep 30, 2022 | 2.86 Bn |
| Jun 30, 2022 | 1.91 Bn |
| Mar 31, 2022 | 2.51 Bn |
| Dec 31, 2021 | 2.86 Bn |
| Sep 30, 2021 | 2.55 Bn |